JP5511385B2 - 細胞骨格活性ｒｈｏキナーゼインヒビター化合物、組成物及び使用 - Google Patents

細胞骨格活性ｒｈｏキナーゼインヒビター化合物、組成物及び使用 Download PDF

Info

Publication number
JP5511385B2
JP5511385B2 JP2009541644A JP2009541644A JP5511385B2 JP 5511385 B2 JP5511385 B2 JP 5511385B2 JP 2009541644 A JP2009541644 A JP 2009541644A JP 2009541644 A JP2009541644 A JP 2009541644A JP 5511385 B2 JP5511385 B2 JP 5511385B2
Authority
JP
Japan
Prior art keywords
compound
heterocycle
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513319A (ja
JP2010513319A5 (https=
Inventor
ダブリュ． ランプ，ジョン
エス． ワトソン，ポール
ジェイ． スレイド，デイビッド
エム． ピーターソン，ワード
エス． クリーン，クリストファー
エル． ビッティトウ，ジェイソン
ブライアン ディキャンプ，ジョナサン
エフ． ペルズ，ニコラス
Original Assignee
インスパイアー ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスパイアー ファーマシューティカルズ，インコーポレイティド filed Critical インスパイアー ファーマシューティカルズ，インコーポレイティド
Publication of JP2010513319A publication Critical patent/JP2010513319A/ja
Publication of JP2010513319A5 publication Critical patent/JP2010513319A5/ja
Application granted granted Critical
Publication of JP5511385B2 publication Critical patent/JP5511385B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009541644A 2006-12-18 2007-12-18 細胞骨格活性ｒｈｏキナーゼインヒビター化合物、組成物及び使用 Expired - Fee Related JP5511385B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87055506P 2006-12-18 2006-12-18
US60/870,555 2006-12-18
US11/958,214 US8071779B2 (en) 2006-12-18 2007-12-17 Cytoskeletal active rho kinase inhibitor compounds, composition and use
US11/958,214 2007-12-17
PCT/US2007/087973 WO2008077057A2 (en) 2006-12-18 2007-12-18 Cytoskeletal active rho kinase inhibitor compounds, composition and use

Publications (3)

Publication Number Publication Date
JP2010513319A JP2010513319A (ja) 2010-04-30
JP2010513319A5 JP2010513319A5 (https=) 2010-12-24
JP5511385B2 true JP5511385B2 (ja) 2014-06-04

Family

ID=39537056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541644A Expired - Fee Related JP5511385B2 (ja) 2006-12-18 2007-12-18 細胞骨格活性ｒｈｏキナーゼインヒビター化合物、組成物及び使用

Country Status (11)

Country Link
US (3) US8071779B2 (https=)
EP (1) EP2099457A4 (https=)
JP (1) JP5511385B2 (https=)
KR (1) KR20090091767A (https=)
CN (2) CN103254172A (https=)
AU (1) AU2007333715B2 (https=)
BR (1) BRPI0720457A2 (https=)
CA (1) CA2672825A1 (https=)
MX (1) MX2009006493A (https=)
RU (1) RU2470928C2 (https=)
WO (1) WO2008077057A2 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
KR101270122B1 (ko) 2007-11-01 2013-05-31 어큐셀라 인코포레이티드 안과 질환 및 장애를 치료하기 위한 아민 유도체 화합물
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2009154940A1 (en) * 2008-06-18 2009-12-23 Inspire Pharmaceuticals, Inc. Process for the preparation of rho-kinase inhibitor compounds
US8410147B2 (en) * 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20090325960A1 (en) * 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
EP2317849A4 (en) * 2008-06-26 2011-11-02 Inspire Pharmaceuticals Inc PROCESS FOR THE TREATMENT OF LUNG DISEASES WITH RHO KINASE INHIBITOR COMPOUNDS
US8207195B2 (en) * 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20100008968A1 (en) * 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20100204210A1 (en) * 2008-12-04 2010-08-12 Scott Sorensen Method for treating pulmonary diseases using rho kinase inhibitor compounds
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
AU2015203100B2 (en) * 2009-06-22 2017-03-16 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
ES2523769T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
CA2781390A1 (en) 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
RU2013107007A (ru) * 2010-07-19 2014-08-27 Инспайр Фармасьютикалз, Инк. Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение
KR20130095263A (ko) * 2010-07-27 2013-08-27 인스파이어 파마슈티컬스 인코퍼레이티드 전구약물 형태의 키나아제 저해제 화합물을 사용하여 안질환을 치료하는 방법
GB201107223D0 (en) 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
LT2788472T (lt) * 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
WO2013096744A1 (en) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US20130168825A1 (en) * 2011-12-30 2013-07-04 Alliance For Sustainable Energy, Llc Fabrication of ionic liquid electrodeposited cu-sn-zn-s-se thin films and method of making
EA038942B1 (ru) 2012-08-28 2021-11-12 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
SG11201503134WA (en) 2012-10-31 2015-05-28 Amakem Nv Novel rock inhibitors
EP2934546A4 (en) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc METHOD OF DISEASE TREATMENT
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
DK3811943T3 (da) 2013-03-15 2023-04-03 Aerie Pharmaceuticals Inc Forbindelse til anvendelse til behandling af øjenlidelser
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
EA035500B1 (ru) 2013-05-17 2020-06-25 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
WO2015118057A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2016057306A1 (en) 2014-10-06 2016-04-14 University Of Houston Rho associated kinase (rock) inhibitors and their use in treating disease
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016180918A1 (en) 2015-05-12 2016-11-17 Platod Combination of pharmacological and microfluidic features for improved platelets production
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
WO2018154133A1 (en) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
KR20190135027A (ko) 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
EP3710431A4 (en) 2017-11-03 2021-07-07 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN108569990A (zh) * 2018-07-09 2018-09-25 张立国 多取代吡咯烷衍生物及其作为Rho激酶抑制剂在癌症中的应用
CN108929258A (zh) * 2018-07-09 2018-12-04 张立国 一种Rho激酶抑制剂及其在癌症治疗中的应用
WO2020033955A1 (en) 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
EP3843845B1 (en) 2018-08-29 2026-03-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020072456A1 (en) * 2018-10-02 2020-04-09 Case Western Reserve University Compounds for treating myelin related disorders
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
CN110215519A (zh) * 2019-07-12 2019-09-10 温州医科大学附属眼视光医院 药物修饰型人工晶状体及其制备方法和应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
US12018016B2 (en) 2021-08-18 2024-06-25 Amgen Inc. Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors
WO2023023534A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524816A (en) * 1984-02-21 1985-06-25 Dentsply Research & Development Corp. Centrifugal casting furnace
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
CN100411686C (zh) 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ATE546143T1 (de) 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
EP1550660A1 (en) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
WO2006135383A2 (en) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1814856A1 (en) * 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives

Also Published As

Publication number Publication date
BRPI0720457A2 (pt) 2014-01-14
EP2099457A4 (en) 2011-08-17
US8604218B2 (en) 2013-12-10
RU2009127798A (ru) 2011-01-27
AU2007333715A1 (en) 2008-06-26
WO2008077057A2 (en) 2008-06-26
JP2010513319A (ja) 2010-04-30
US8071779B2 (en) 2011-12-06
WO2008077057A3 (en) 2008-08-21
CN101583361B (zh) 2013-01-23
MX2009006493A (es) 2009-09-10
CN103254172A (zh) 2013-08-21
RU2470928C2 (ru) 2012-12-27
KR20090091767A (ko) 2009-08-28
US8604205B2 (en) 2013-12-10
CA2672825A1 (en) 2008-06-26
EP2099457A2 (en) 2009-09-16
US20130012543A1 (en) 2013-01-10
US20080214614A1 (en) 2008-09-04
US20120046275A1 (en) 2012-02-23
CN101583361A (zh) 2009-11-18
AU2007333715B2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
JP5511385B2 (ja) 細胞骨格活性ｒｈｏキナーゼインヒビター化合物、組成物及び使用
US20130131059A1 (en) Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
US20130131106A1 (en) Bifunctional rho kinase inhibitor compounds, composition and use
JP7083073B2 (ja) インテグリンアンタゴニスト
EA008501B1 (ru) 2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
WO1999059499A2 (en) Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
CN101160315A (zh) 细胞骨架的活性化合物，组合物及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130411

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130412

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140325

R150 Certificate of patent or registration of utility model

Ref document number: 5511385

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees